Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

DiaMedica Therapeutics Inc DMAC

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.


NDAQ:DMAC - Post by User

Bullboard Posts
Comment by RockLobster1on Jun 06, 2019 4:52pm
54 Views
Post# 29803934

RE:RE:RE:Reality FINALLY Sinks in

RE:RE:RE:Reality FINALLY Sinks in On Dec 7 last year they sold 4m shares at $4 US... It killed the stock... the markets had been terrible going into December and they raised at a low price into a falling market. The 4 m shares was over 50% dilution... that's huge, usually i dont see more than 10-15%. I think a better strategy was to just raise a small amount if really needed and then wait a few months. But I don't know their reasoning of course so I'm just theorizing as a small holder. Just seems it could have been done better. that said... we had a very good day today on good buying at the end. Hope we can stay over $3 usd and head to the issue price at $4 as a start. Seems like a good price to add some. I'll have to look further but how long will $16m USD take them? Seems a good amount and hopefully no more financing needed for a while until after good results and a better price. good luck
Bullboard Posts